These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 18437096)

  • 1. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice.
    Dai XY; Ou X; Hao XR; Cao DL; Tang YL; Hu YW; Li XX; Tang CK
    J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
    Ou X; Dai X; Long Z; Tang Y; Cao D; Hao X; Hu Y; Li X; Tang C
    Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.
    Verschuren L; de Vries-van der Weij J; Zadelaar S; Kleemann R; Kooistra T
    J Lipid Res; 2009 Feb; 50(2):301-11. PubMed ID: 18757914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential.
    Zanotti I; Potì F; Pedrelli M; Favari E; Moleri E; Franceschini G; Calabresi L; Bernini F
    J Lipid Res; 2008 May; 49(5):954-60. PubMed ID: 18252848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes.
    Laffitte BA; Repa JJ; Joseph SB; Wilpitz DC; Kast HR; Mangelsdorf DJ; Tontonoz P
    Proc Natl Acad Sci U S A; 2001 Jan; 98(2):507-12. PubMed ID: 11149950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.
    Gui Y; Yao S; Yan H; Hu L; Yu C; Gao F; Xi C; Li H; Ye Y; Wang Y
    Cardiovasc Res; 2016 Oct; 112(1):502-14. PubMed ID: 27460841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions.
    Marleau S; Harb D; Bujold K; Avallone R; Iken K; Wang Y; Demers A; Sirois MG; Febbraio M; Silverstein RL; Tremblay A; Ong H
    FASEB J; 2005 Nov; 19(13):1869-71. PubMed ID: 16123174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of ATP binding cassette protein A1 expression and ApoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages.
    Wang MD; Franklin V; Sundaram M; Kiss RS; Ho K; Gallant M; Marcel YL
    J Biol Chem; 2007 Aug; 282(31):22525-33. PubMed ID: 17553802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.
    Kratzer A; Buchebner M; Pfeifer T; Becker TM; Uray G; Miyazaki M; Miyazaki-Anzai S; Ebner B; Chandak PG; Kadam RS; Calayir E; Rathke N; Ahammer H; Radovic B; Trauner M; Hoefler G; Kompella UB; Fauler G; Levi M; Levak-Frank S; Kostner GM; Kratky D
    J Lipid Res; 2009 Feb; 50(2):312-26. PubMed ID: 18812595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATP-binding cassette transporter A1.
    Lv YC; Yang J; Yao F; Xie W; Tang YY; Ouyang XP; He PP; Tan YL; Li L; Zhang M; Liu D; Cayabyab FS; Zheng XL; Tang CK
    Atherosclerosis; 2015 May; 240(1):80-9. PubMed ID: 25765596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiatherosclerotic effect of farnesoid X receptor.
    Mencarelli A; Renga B; Distrutti E; Fiorucci S
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages.
    Rigamonti E; Helin L; Lestavel S; Mutka AL; Lepore M; Fontaine C; Bouhlel MA; Bultel S; Fruchart JC; Ikonen E; Clavey V; Staels B; Chinetti-Gbaguidi G
    Circ Res; 2005 Sep; 97(7):682-9. PubMed ID: 16141411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver X receptor and retinoic X receptor agonists modulate the expression of genes involved in lipid metabolism in human endothelial cells.
    Norata GD; Ongari M; Uboldi P; Pellegatta F; Catapano AL
    Int J Mol Med; 2005 Oct; 16(4):717-22. PubMed ID: 16142410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.
    Song G; Liu J; Zhao Z; Yu Y; Tian H; Yao S; Li G; Qin S
    Lipids Health Dis; 2011 Jan; 10():8. PubMed ID: 21241519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.
    Peng D; Hiipakka RA; Dai Q; Guo J; Reardon CA; Getz GS; Liao S
    J Pharmacol Exp Ther; 2008 Nov; 327(2):332-42. PubMed ID: 18723776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of liver X receptor induces macrophage interleukin-5 expression.
    Chen Y; Duan Y; Kang Y; Yang X; Jiang M; Zhang L; Li G; Yin Z; Hu W; Dong P; Li X; Hajjar DP; Han J
    J Biol Chem; 2012 Dec; 287(52):43340-50. PubMed ID: 23150660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages.
    Shridas P; Bailey WM; Gizard F; Oslund RC; Gelb MH; Bruemmer D; Webb NR
    Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):2014-21. PubMed ID: 20844270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.